Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
31,306,673
-
Total 13F shares
-
15,216,182
-
Share change
-
+534,746
-
Total reported value
-
$191,059,731
-
Price per share
-
$12.69
-
Number of holders
-
39
-
Value change
-
+$6,824,904
-
Number of buys
-
31
-
Number of sells
-
7
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) as of Q1 2023
As of 31 Mar 2023,
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,216,182 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Sands Capital Ventures, LLC, CITADEL ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, FEDERATED HERMES, INC., MARSHALL WACE, LLP, NEA Management Company, LLC, BlackRock Inc., and VANGUARD GROUP INC.
This page lists
39
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.